A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a Single Injection of Rexlemestrocel-L Alone or Combined With Hyaluronic Acid (HA) in Subjects With Chronic Low Back Pain
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 26 Apr 2018
At a glance
- Drugs Rexlemestrocel-L (Primary) ; Hyaluronic acid
- Indications Back pain; Intervertebral disc degeneration
- Focus Registrational; Therapeutic Use
- Sponsors Mesoblast
- 19 Apr 2018 Planned End Date changed from 1 Oct 2020 to 1 Mar 2021.
- 19 Apr 2018 Planned primary completion date changed from 1 Oct 2019 to 1 Mar 2020.
- 28 Mar 2018 Status changed from recruiting to active, no longer recruiting.